68Ga-PSMA-11 PET/CT预测不利中危和高危前列腺癌总生存:IAEA多中心研究
该前瞻性多中心研究纳入11国775例新诊断不利中危或高危前列腺癌患者,行68Ga-PSMA-11 PET/CT分期并分为N0M0、N1M0、NxM1三组,比较临床随访数据。结果显示分期与生化复发率、2年无事件生存率和2年总生存率显著相关,且PET/CT状态是唯一显著预后因素。
要点
- 68Ga-PSMA-11 PET/CT分期可区分不同生存结局的前列腺癌患者。
- NxM1患者2年总生存率86.8%,低于N0M0的99.3%和N1M0的99.2%(P<0.001)。
- PET/CT状态是生存结局的唯一显著预后因素。
核心结论
- 68Ga-PSMA-11 PET/CT是不利中危或高危前列腺癌患者稳健且独立的预后标志物,可能有助于定制治疗并改善结局。
研究设计与样本
- 国际原子能机构支持的前瞻性多中心试验,纳入11国775例新诊断不利中危或高危前列腺癌且为根治性前列腺切除术候选者的患者。
主要发现
- 生化复发率分别为N0M0 35.4%、N1M0 68.2%、NxM1 77.2%。
- 2年无事件生存率分别为N0M0 56.6%、N1M0 43.9%、NxM1 26.0%。
- 2年总生存率分别为N0M0 99.3%、N1M0 99.2%、NxM1 86.8%(P < 0.001)。
- 68Ga-PSMA-11 PET/CT状态是生存结局的唯一显著预后因素。
临床怎么用
- 对于不利中危或高危前列腺癌根治术候选者,68Ga-PSMA-11 PET/CT分期结果可用于预后分层并辅助治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although multiple studies have demonstrated the accuracy of 68Ga-PSMA-11 PET/CT, its ability to predict survival outcomes and treatment response remains unclear. This study assessed the prognostic value of 68Ga-PSMA-11 PET/CT in staging unfavorable intermediate- or high-risk prostate cancer (PCa) in patients who are candidates for radical prostatectomy. Methods: This prospective multicenter trial supported by the International Atomic Energy Agency enrolled 775 patients across 11 countries with newly diagnosed, unfavorable intermediate- or high-risk PCa. Patients underwent 68Ga-PSMA-11 PET/CT, after which their disease was categorized as N0M0 (no involvement of local nodes and no metastases), N1M0 (pelvic lymph node involvement), or NxM1 (distant metastases). These findings were then compared with clinical follow-up data. Results: Biochemical recurrence rates were 35.4% (N0M0), 68.2% (N1M0), and 77.2% (NxM1). Two-year event-free survival rates were 56.6%, 43.9%, and 26.0% in patients with N0M0, N1M0, and NxM1 disease, respectively. Two-year overall survival rates were 99.3% in patients with N0M0 disease, 99.2% in those with N1M0 disease, and 86.8% in those with NxM1 disease (P < 0.001). 68Ga-PSMA-11 PET/CT status was the only significant prognostic factor for survival outcomes. Conclusion: 68Ga-PSMA-11 PET/CT is a robust and independent prognostic marker in patients with unfavorable intermediate- or high-risk PCa and may help tailor treatments and improve outcomes.
引用
- Cerci JJ, Fanti S, Lobato EE, et al. 68Ga-PSMA-11 PET/CT for Initial Staging of Unfavorable Intermediate-Risk and High-Risk Prostate Cancer Predicts Overall Survival: An IAEA Multicenter Study. J Nucl Med. 2026. PMID: 41611477. doi:10.2967/jnumed.125.271173
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。